Shopping Cart 0
Cart Subtotal
USD 0

CymaBay Therapeutics Inc (CBAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company's pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

CymaBay Therapeutics Inc (CBAY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11

Partnerships 12

HistoIndex and CymaBay Therapeutics Enter into Partnership 12

Equity Offering 13

CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13

CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15

CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17

CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18

CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19

CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21

CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23

CymaBay Therapeutics Inc-Key Competitors 24

CymaBay Therapeutics Inc-Key Employees 25

CymaBay Therapeutics Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Nov 06, 2018: CymaBay reports third quarter 2018 financial results and provides corporate update 27

Nov 06, 2018: Cymabay reports third quarter 2018 financial results and provides corporate update 29

Aug 09, 2018: Cymabay reports second quarter 2018 financial results and provides corporate update 31

May 08, 2018: CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update 33

Mar 15, 2018: CymaBay Announces Fourth Quarter and Fiscal 2017 Financial Results 34

Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates 36

Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results 40

Corporate Communications 41

Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. 41

Product News 42

10/31/2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer 42

06/19/2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 43

01/08/2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis 44

01/08/2018: CymaBay Therapeutics Receives USD 5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America 45

Product Approvals 46

Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis 46

Clinical Trials 47

May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis 47

Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 48

Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis 50

Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting 51

Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology 52

Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis 53

Apr 13, 2017: CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 54

Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11

HistoIndex and CymaBay Therapeutics Enter into Partnership 12

CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13

CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15

CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17

CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18

CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19

CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21

CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23

CymaBay Therapeutics Inc, Key Competitors 24

CymaBay Therapeutics Inc, Key Employees 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CymaBay Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company's pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

CymaBay Therapeutics Inc (CBAY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11

Partnerships 12

HistoIndex and CymaBay Therapeutics Enter into Partnership 12

Equity Offering 13

CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13

CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15

CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17

CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18

CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19

CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21

CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23

CymaBay Therapeutics Inc-Key Competitors 24

CymaBay Therapeutics Inc-Key Employees 25

CymaBay Therapeutics Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Nov 06, 2018: CymaBay reports third quarter 2018 financial results and provides corporate update 27

Nov 06, 2018: Cymabay reports third quarter 2018 financial results and provides corporate update 29

Aug 09, 2018: Cymabay reports second quarter 2018 financial results and provides corporate update 31

May 08, 2018: CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update 33

Mar 15, 2018: CymaBay Announces Fourth Quarter and Fiscal 2017 Financial Results 34

Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates 36

Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results 40

Corporate Communications 41

Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. 41

Product News 42

10/31/2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer 42

06/19/2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 43

01/08/2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis 44

01/08/2018: CymaBay Therapeutics Receives USD 5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America 45

Product Approvals 46

Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis 46

Clinical Trials 47

May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis 47

Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 48

Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis 50

Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting 51

Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology 52

Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis 53

Apr 13, 2017: CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 54

Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CymaBay Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11

HistoIndex and CymaBay Therapeutics Enter into Partnership 12

CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13

CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15

CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17

CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18

CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19

CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21

CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23

CymaBay Therapeutics Inc, Key Competitors 24

CymaBay Therapeutics Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CymaBay Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.